Navigation Links
Statins reduce CV events in CAD patients with very low LDL-C
Date:8/31/2013

Dr Nakano said: "Many randomised clinical trials, such as Treating to New Targets (TNT) and PROVE IT-TIMI, have shown that aggressive cholesterol lowering with statins improves clinical outcomes in patients with CAD and high LDL-C levels.1,2 But until now it was not known whether aggressive lipid lowering with statins would also benefit CAD patients with very low LDL-C levels."

The current study used the Ibaraki Cardiovascular Assessment Study (ICAS), a registry of 2,238 patients from 12 hospitals in the Ibaraki region of Japan, who between 0 and 1 month underwent percutaneous coronary interventions. Based on serum LDL-C levels at initial presentation participants were classified into three groups: very low (<70 mg/dl, n=214); low (71-100 mg/dl, n=669); and high (>101 mg/dl, n= 1,355). Decisions of whether to prescribe statins or not, as well as the type and dose, were left to the discretion of treating physicians.

Patients were followed up for a maximum of 3 years. The efficacy of statin treatment was analysed on the composite outcome of Major Cardiovascular Events (MACE), defined as all cause mortality, non-fatal myocardial infarction and non-fatal stroke.

Statins were prescribed in 68% of patients (143) with very low LDL-C, 67% of patients (450) with low LDL-C and 67% of patients (913) with high LDL-C. A total of 204 patients experienced MACE during the median follow-up of 404 days.

The results of a Kaplan-Meier estimate show that three years of statin treatment produced significant reductions in the incidence of MACE in all three groups (p<0.001 for all groups). A Cox regression hazard analysis adjusted for age and gender showed that statins were the main determinant of better outcome regardless of the LDL-C level (p<0.01).

Dr Nakano said: "Our study shows that CAD patients with very low LDL-C levels at initial presentation also benefit from statin treatment. We speculate that statins prevent the enlargement of atherosclerotic plaques and plaque disruption in these patients."

She added: "Some doctors have been hesitant to prescribe statins in patients with very low LDL-C because of uncertain benefit and the risk of side effects with statins. But our findings suggest that all CAD patients should receive statins to reduce their risk of future cardiovascular events."

Dr Nakano concluded: "The next step should now be to initiate a randomised controlled trial of statin use in patients with CAD and very low LDL-C levels. This trial should be designed to confirm the benefits of statins for preventing future cardiovascular events in these patients, and to identify which type and dose of statins are most beneficial."


'/>"/>

Contact: Celine Colas
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Statins prevent cataracts
2. Specialized treatment helps cholesterol patients who suffer side effects from statins
3. Could Statins Raise Diabetes Risk?
4. Statins May Hamper Workout Results
5. Zocor Side Effects Update: Bernstein Liebhard LLP Comments on New Study Linking Kidney Problems to High Doses of Zocor, Other Statins
6. High-Dose Statins Linked to Acute Kidney Damage
7. TV Ads for Statins May Drive Overtreatment
8. VABC Responds to Study on Use of Cholesterol Lowering Drug Statins on Cancer Patients
9. UT MD Anderson study finds link between statins and improved survival in inflammatory breast cancer
10. Statins Plus Exercise Best at Lowering Cholesterol, Study Finds
11. Statins have potential to treat an autoimmune clotting disorder called antiphospholipid syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... 2016 , ... The Society for Women’s Health Research (SWHR) announced that its ... role. , “No one in Washington led the way to advance women’s health research ... MD, PhD. “We offer our deep gratitude to Phyllis for her passion and performance ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... on its Chesterfield, Missouri, campus, Standard Process Inc. awarded $6,000 in ... Siewert and Chloe Tillman. Each student is in her fifth trimester of classes ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley ... worldwide for people who are blind or visually impaired, announces the election of ... President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, a ...
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a leading treatment ... to announce the launch of its new extended care program, Fifth Circle. Available for ... Four Circles or another primary treatment program, Fifth Circle is designed to foster the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... 19, 2016 BioLineRx Ltd. (NASDAQ/TASE: ... the treatment of multiple cancer and hematological indications, will ... An abstract titled " Clinical response in relapsed/refractory AML ... by BL-8040, a potent CXCR4 antagonist; results of a ... presentation at the European Hematology Association 21st Congress, to ...
(Date:5/19/2016)... and CAMBRIDGE, Massachusetts , May 19, ... in the development of pharmaceuticals and diagnostics based on the ... a new office in Cambridge, MA ... US. The office is located at Kendall Square, ... industry, well-known as the global hub for transforming scientific insights ...
(Date:5/18/2016)... May 19, 2016 ... Research Report initially provides a basic overview ... and manufacturing technology, post which the report ... in the market. Complete report ... pages providing 8 company profiles and 98 ...
Breaking Medicine Technology: